TIRZEPATIDE (Mounjaro, Zepbound) prior authorization at Centene

The PA criteria you'll need to meet

Centene reviews TIRZEPATIDE (Mounjaro, Zepbound) prior authorizations against its medical policy for Glucose-dependent Insulinotropic Polypeptide Receptor Agonist. Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.

Documentation packet checklist

• Chart note with diagnosis (ICD-10 code) and clinical severity markers
• Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
• Prior treatment history including dosing, duration, and reason for discontinuation
• Relevant labs, imaging, or assessment scores supporting medical necessity
• Prescriber attestation linking the FDA-approved indication to the patient's presentation
• Centene's medical policy URL referenced in the cover letter

Centene's common denial patterns

Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:

• Marketplace network adequacy issues
• Medicaid step therapy
• Specialty drug exclusions

TIRZEPATIDE (Mounjaro, Zepbound)-specific denial patterns and context

Across payers (not just Centene), TIRZEPATIDE (Mounjaro, Zepbound)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:

• Weight-loss exclusion (Zepbound)
• Step therapy requiring GLP-1 first
• Quantity limit

Sold as Mounjaro (T2D) and Zepbound (chronic weight management). Dual GIP/GLP-1 receptor agonist.

Manufacturer patient-assistance program: Lilly Cares — relevant when a Centene denial sticks and the patient needs bridge access while appealing.

How Centene approaches GLP-1 receptor agonists PAs

Centene's GLP-1 receptor agonists reviewer typically anchors TIRZEPATIDE (ZEPBOUND) prior-auth decisions on medicaid step therapy and specialty drug exclusions. Pharmacy-benefit review for TIRZEPATIDE (ZEPBOUND) at Centene is routed through Envolve Pharmacy Solutions / state-specific Medicaid PBMs. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 60-day internal-appeal window begins from the denial date. Plans including Centene commonly distinguish T2D-indication PAs (Ozempic, Mounjaro, Trulicity) from weight-management-indication PAs (Wegovy, Zepbound, Saxenda) — the second path triggers benefit-exclusion review under the plan's anti-obesity-medication carve-out language. Centene is domiciled in MO, so unresolved appeals escalate to the MO insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Largest Medicaid MCO in US.

If the PA is denied

Centene gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://ambetterhealth.com/provider-resources) with the same packet plus a peer-reviewed citation supporting TIRZEPATIDE (Mounjaro, Zepbound)for the patient's indication.

Medicare Advantage path: if Centene misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.

Centene as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. For TIRZEPATIDE (ZEPBOUND), the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.

Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Centene denial on DenialHelp.

Contact Centene

• Provider portal: https://ambetterhealth.com/provider-resources